查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1544659

發炎性腸道疾病治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Inflammatory Bowel Disease Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 100 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於 IBD 的流行和人們對該疾病的認知不斷提高，預計 2024 年至 2032 年全球發炎性腸道疾病治療市場的複合年成長率將達到 6.1%。根據美國國立衛生研究院 (NIH) 的報告，2023 年全球生物技術研發支出將達到 4,000 億美元。 這種投資熱潮支持了 IBD 創新療法的開發，例如生物製劑和標靶治療。不斷擴大的患者群體和對個人化治療選擇的需求正在創造積極的行業前景。

生物技術和製藥的進步帶來了創新療法，可積極改善患者的治療效果。此外，製藥公司對研發的投資不斷增加，以及研究機構和生技公司之間合作的激增，正在加速發炎性腸道疾病治療市場的成長。

發炎性腸道疾病治療產業根據治療類型、藥物類別、給藥途徑、配銷通路和地區進行分類。

到 2032 年，由於診斷病例數量的增加和人們對該疾病的認知不斷提高，潰瘍性結腸炎細分市場將經歷可觀的成長。潰瘍性結腸炎是一種影響結腸的慢性炎症，通常需要專門的治療策略，從而導致對標靶治療和治療進展的需求增加。隨著醫療保健提供者和患者尋求更有效和量身定做的治療方案來控制症狀和改善生活品質，對潰瘍性結腸炎的關注不斷加強，從而擴大了細分市場的成長。增強的診斷技術和患者教育促進了需求的增加。

到 2032 年，由於患者可及性和便利性的提高，電子商務領域將佔據重要的發炎性腸道疾病治療市場。線上平台有助於直接購買藥物和治療相關產品，從而更容易獲得各種專業和利基治療。這種增加的可用性對於偏遠或服務不足地區的患者是有益的，因為這些地區獲得實體藥房的機會可能有限。電子商務管道提供簡化的購買流程，並提供詳細的資訊和患者評論，幫助消費者做出明智的決定。

在研究期間，歐洲發炎性腸道疾病治療市場將錄得令人印象深刻的成長率，這得益於不斷增加的醫療保健支出，提高了先進治療的可負擔性。該地區強力的監管框架支持新療法的開發和批准，促進治療領域的創新。 IBD 在歐洲的盛行率不斷上升，加上公眾意識的提高和早期診斷，導致對有效管理解決方案的需求更高。完善的研究機構和製藥公司網路正在加速新療法的開發，幫助市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • IBD 盛行率增加
      • 技術進步
      • 優惠報銷政策
      • 對 IBD 症狀的認知不斷提高並進行早期診斷
    • 產業陷阱與挑戰
      • 嚴格的監管場景
      • 治療費用高
  • 成長潛力分析
  • 報銷場景
  • 監管環境
  • 流行病學情景
  • 未來市場趨勢
  • 管道分析
  • 2023 年定價分析
  • 品牌分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

  • 主要趨勢
  • 克隆氏症
  • 潰瘍性結腸炎

第 6 章：市場估計與預測：按藥物類別，2021 - 2032 年

  • 主要趨勢
  • 腫瘤壞死因子抑制劑
  • 氨基水楊酸鹽
  • 皮質類固醇
  • 白血球介素抑制劑
  • JAK抑制劑
  • 抗整合素
  • 其他藥物類別

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

  • 主要趨勢
  • 可注射
  • 口服

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • AbbVie Inc
  • Amgen Inc.
  • Biogen
  • CELLTRION INC
  • Dr Falk Pharma UK Ltd
  • Ferring B.V.
  • Ferring B.V.
  • Johnson and Johnson
  • Lilly
  • Novartis AG
  • Pfizer Inc
  • Takeda Pharmaceutical Company Limited
  • Tillotts Pharma AG
  • UCB Group
簡介目錄
Product Code: 10194

Global Inflammatory Bowel Disease Treatment Market is projected to achieve a 6.1% CAGR from 2024 to 2032, catapulted by the prevalence of IBD and growing awareness of this condition. As per the U.S. National Institutes of Health (NIH) report, global spending on biotechnology R and D reached USD 400 billion in 2023. This upsurge in investment supports the development of innovative therapies for IBD, such as biologics and targeted treatments. The expanding patient population and the need for personalized treatment options are creating a positive industry outlook.

Advances in biotechnology and pharmaceuticals have resulted in innovative therapies that are positively improving patient outcomes. Additionally, growing investment in research and development by pharmaceutical companies and a surge in collaborations between research institutions and biotech firms are accelerating inflammatory bowel disease treatment market growth.

The inflammatory bowel disease treatment industry is sorted based on treatment type, drug class, route of administration, distribution channel, and region.

The ulcerative colitis segment will experience a decent growth rate through 2032, due to an increase in the number of diagnosed cases and growing awareness of the condition. Ulcerative colitis, a chronic inflammatory condition affecting the colon, often requires specialized management strategies, leading to heightened demand for targeted treatments and therapeutic advancements. As healthcare providers and patients seek more effective and tailored treatment options to manage symptoms and improve quality of life, the focus on ulcerative colitis has intensified, amplifying segment growth. Enhanced diagnostic techniques and patient education are contributing to the increased demand.

By 2032, the e-commerce segment will hold a significant inflammatory bowel disease treatment market share, owing to improved patient accessibility and convenience. Online platforms facilitate the direct purchase of medications and treatment-related products, allowing for easier access to a wide range of specialty and niche treatments. This increased availability is beneficial for patients in remote or underserved areas, where access to physical pharmacies may be limited. E-commerce channels offer a streamlined purchasing process and provide detailed information and patient reviews, helping consumers make informed decisions.

Europe inflammatory bowel disease treatment market will record an impressive growth rate over the study period, bolstered by the increasing healthcare expenditure enhancing the affordability of advanced treatments. The strong regulatory framework in the region supports the development and approval of new therapies, fostering innovation in the treatment landscape. The rising prevalence of IBD in Europe, coupled with greater public awareness and early diagnosis, is leading to a higher demand for effective management solutions. A well-established network of research institutions and pharmaceutical companies is accelerating the development of novel treatments, aiding market growth.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of IBD
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Favorable reimbursement policies
      • 3.2.1.4 Growing awareness and early diagnosis of IBD symptoms
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory scenario
      • 3.2.2.2 High cost of treatment
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Regulatory landscape
  • 3.6 Epidemiological scenario
  • 3.7 Future market trends
  • 3.8 Pipeline analysis
  • 3.9 Pricing analysis, 2023
  • 3.10 Brand analysis
  • 3.11 Porter's analysis
  • 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Crohn's disease
  • 5.3 Ulcerative colitis

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 TNF inhibitors
  • 6.3 Aminosalicylates
  • 6.4 Corticosteroids
  • 6.5 IL inhibitors
  • 6.6 JAK inhibitors
  • 6.7 Anti-integrin
  • 6.8 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Injectable
  • 7.3 Oral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacy
  • 8.3 Retail pharmacy
  • 8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 AbbVie Inc
  • 10.2 Amgen Inc.
  • 10.3 Biogen
  • 10.4 CELLTRION INC
  • 10.5 Dr Falk Pharma UK Ltd
  • 10.6 Ferring B.V.
  • 10.7 Ferring B.V.
  • 10.8 Johnson and Johnson
  • 10.9 Lilly
  • 10.10 Novartis AG
  • 10.11 Pfizer Inc
  • 10.12 Takeda Pharmaceutical Company Limited
  • 10.13 Tillotts Pharma AG
  • 10.14 UCB Group